Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Cash from Financing Activities: 2017-2020

Historic Cash from Financing Activities for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to $6.7 million.

  • Monopar Therapeutics' Cash from Financing Activities rose 50810.13% to $6.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was $17.6 million, marking a year-over-year increase of 7252.68%. This contributed to the annual value of $59.3 million for FY2024, which is 2824.80% up from last year.
  • Latest data reveals that Monopar Therapeutics reported Cash from Financing Activities of $6.7 million as of Q3 2020, which was up 611.62% from $946,404 recorded in Q2 2020.
  • In the past 5 years, Monopar Therapeutics' Cash from Financing Activities registered a high of $9.4 million during Q4 2019, and its lowest value of -$206,270 during Q4 2018.
  • Over the past 3 years, Monopar Therapeutics' median Cash from Financing Activities value was $247,861 (recorded in 2019), while the average stood at $2.2 million.
  • Per our database at Business Quant, Monopar Therapeutics' Cash from Financing Activities tumbled by 2,162.49% in 2018 and then surged by 50,810.13% in 2020.
  • Over the past 4 years, Monopar Therapeutics' Cash from Financing Activities (Quarterly) stood at $10,001 in 2017, then crashed by 2,162.49% to -$206,270 in 2018, then soared by 4,650.77% to $9.4 million in 2019, then spiked by 50,810.13% to $6.7 million in 2020.
  • Its last three reported values are $6.7 million in Q3 2020, $946,404 for Q2 2020, and $508,044 during Q1 2020.